300639 Guangdong Hybribio Biotech
- 5.99
- +0.03+0.50%
Guangdong Hybribio Biotech News
Further Weakness as Guangdong Hybribio BiotechLtd (SZSE:300639) Drops 9.9% This Week, Taking Three-year Losses to 57%
Guangdong Hybribio Biotech (300639.SZ): Has not yet begun the first buyback.
On December 2, Gelonhui | guangdong hybribio biotech (300639.SZ) announced that as of November 30, 2024, the company's third centralized competitive bidding method to repurchase company shares in 2024 has not yet begun the first repurchase.
Guangdong Hybribio Biotech (300639.SZ): The company and its subsidiaries have been granted an invention patent.
grlonghui December 2nd | guangdong hybribio biotech (300639.SZ) announced that the company and its subsidiaries were granted one invention patent in November 2024, with the invention patent titled a method for isolating placenta trophoblast cells from cervical sloughing cells of pregnant women. The invention patent discloses a method for isolating placenta trophoblast cells from cervical sloughing cells of pregnant women, which is based on the specific antigens and combinations expressed on the surface or intracellularly of trophoblast cells, and utilizes a designed microfluidic sorting chip or flow cytometer to sort the cell suspension prepared from cervical sloughing cell samples of pregnant women, thereby obtaining purified placenta.
Hybribio Biotech to Apply for 70 Million Yuan for Share Buyback Plan
Guangdong Hybribio Biotech (300639.SZ): Plans to spend 0.05 billion yuan to -0.1 billion yuan to buy back shares.
Gelonghui, November 14 – Guangdong Hybribio Biotech (300639.SZ) announced that the company plans to use its own funds and bank special repurchase loan funds to repurchase a portion of its shares through a centralized bidding trading method (hereinafter referred to as "this repurchase plan"). The repurchased shares will be used to maintain the company's value and the rights of shareholders. The total amount of funds for repurchasing shares and the source of funds will be no less than 50 million RMB (inclusive) and no more than 100 million RMB (inclusive) from its own funds and bank special repurchase loan funds. The price for repurchased shares will not exceed 9.00 RMB/share (inclusive). The implementation period for the repurchased shares starts from
Guangdong Hybribio Biotech (300639.SZ): The company currently has no test reagents related to dengue virus.
On November 14, Gelonghui reported that guangdong hybribio biotech (300639.SZ) stated on the investor interaction platform that the company currently has no test reagents related to the dengue virus, but its medical laboratory has the capability to perform laboratory tests for the dengue virus.
Individual Investors Are Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥378m Last Week
Guangdong Hybribio Biotech (300639.SZ): The company and its subsidiaries have been granted two invention patent authorizations.
Galonnell 31st October, guangdong hybribio biotech (300639.SZ) announced that the company and its subsidiaries obtained 2 invention patents in October 2024, including a method for separating placental nourishing layer cells from pregnant women's cervical shedding cells, as well as a chloroquine gel and its preparation method and application.
Capbio: Report for the third quarter of 2024
Guangdong Hybribio Biotech (300639.SZ): The net loss in the first three quarters was 0.262 billion yuan.
On October 29, Gelonhui reported that Guangdong Hybribio Biotech (300639.SZ) released its third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.61 billion yuan, a decrease of 28.26% year-on-year; the net income attributable to shareholders of the listed company was a loss of 0.262 billion yuan, a decrease of 252.19% year-on-year; the net income after deducting non-recurring gains and losses was a loss of 0.27 billion yuan, a decrease of 276.98% year-on-year; the basic earnings per share was -0.4068 yuan per share.
Guangdong Hybribio Biotech (300639.SZ) released its performance for the first three quarters, with a net loss of 0.262 billion yuan.
Guangdong Hybribio Biotech (300639.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters reaching 6...
Improved Revenues Required Before Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) Stock's 45% Jump Looks Justified
Guangdong Hybribio Biotech (300639.SZ): The company and its subsidiaries have been granted a patent for invention.
Gelonghui September 30th | Guangdong Hybribio Biotech (300639.SZ) announced that the company and its subsidiaries obtained an invention patent in September 2024. The invention patent is for a reagent kit and its application for extracting genomic DNA from dried blood spots using a magnetic bead method. This invention relates to the technical field of nucleic acid extraction, providing a reagent kit and its application for extracting genomic DNA from dried blood spots using a magnetic bead method. The kit consists of a nucleic acid releasing agent, lysis solution, magnetic beads, wash solution I, wash solution II, and elution solution. This invention adds NaOH and guanidine hydrochloride to the nucleic acid releasing agent to rapidly lyse cells, release nucleic acids, and at the same time
Strong Week for Guangdong Hybribio BiotechLtd (SZSE:300639) Shareholders Doesn't Alleviate Pain of Three-year Loss
Hybribio Biotech Unit Gets Nod to Trial Chloroquine Phosphate Gel
Guangdong Hybribio Biotech (300639.SZ): The wholly-owned subsidiary, Chloroquine Phosphate Gel, has obtained the Notice of Approval for Clinical Trials of Medicines.
Gelonghui September 20th | Guangdong Hybribio Biotech (300639.SZ) announced that recently, its wholly-owned subsidiary Guangzhou Guangdong Hybribio Technology Co., Ltd. has received the drug clinical trial approval notice for "Chloroquine Phosphate Gel" issued by the National Medical Products Administration, allowing the product to conduct clinical trials for high-risk HPV virus infections.
Guangdong Hybribio Biotech Unit Gets China Nod for HPV Diagnostic Kit
Guangdong Hybribio Biotech (300639.SZ): The company and its subsidiaries have been granted 2 invention patent authorizations.
On September 2, Guangdong Hybribio Biotech (300639.SZ) announced that the company and its subsidiaries obtained a total of 2 patents in August 2024. The patent names are respectively a method for predicting mitochondrial diseases and a system for predicting mitochondrial diseases, and a sliding compression reaction chamber mechanism.
Capbio: 2024 Semi-Annual Report
Capbio: 2024 Semi-Annual Report Summary
No Data
